Published in Biochem J on May 01, 2009
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A (2009) 3.39
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res (2010) 1.56
The PCSK9 decade. J Lipid Res (2012) 1.50
A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem (2010) 1.32
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res (2010) 1.29
An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci (2012) 1.15
Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci U S A (2009) 1.12
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis (2011) 1.03
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J Lipid Res (2011) 1.01
Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. J Biol Chem (2012) 0.99
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther (2013) 0.94
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res (2009) 0.93
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. J Lipid Res (2010) 0.91
Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J Biol Chem (2011) 0.90
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. J Lipid Res (2014) 0.86
Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. J Lipid Res (2012) 0.82
PCSK9 inhibition: the way forward in the treatment of dyslipidemia. BMC Med (2015) 0.79
PCSK9 inhibitors in the prevention of cardiovascular disease. J Thromb Thrombolysis (2016) 0.79
New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people? World J Hepatol (2013) 0.77
Novel method for reducing plasma cholesterol: a ligand replacement therapy. Clin Lipidol (2015) 0.77
PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol (2017) 0.75
The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Glob Cardiol Sci Pract (2017) 0.75
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet (2003) 11.67
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A (2005) 4.56
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest (2003) 4.42
NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem (2004) 4.37
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2004) 4.08
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem (2004) 3.93
Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci (2007) 3.59
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest (2006) 3.54
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem (2007) 3.45
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A (2005) 3.15
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol (2007) 2.76
Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci U S A (1999) 2.55
Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A (2008) 2.42
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic (2007) 2.09
The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem (2006) 2.07
The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure (2007) 1.99
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res (2007) 1.99
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem (2007) 1.97
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem (2007) 1.92
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet (2006) 1.89
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol (2006) 1.85
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J (2007) 1.48
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun (2008) 1.47
Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem (2008) 1.41
PCSK9: an enigmatic protease. Biochim Biophys Acta (2008) 1.02
Efficient expression of secreted proteases via recombinant BacMam virus. Protein Expr Purif (2006) 0.93
Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs (2008) 0.80
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res (2003) 2.29
Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A (2007) 2.05
Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2003) 2.03
Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J (2004) 1.98
Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem (2005) 1.73
The prion protein and lipid rafts. Mol Membr Biol (2006) 1.54
The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci (2002) 1.51
Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J Cell Sci (2005) 1.38
Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis. Traffic (2010) 1.36
Dual mechanisms for shedding of the cellular prion protein. J Biol Chem (2004) 1.32
Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. J Gen Virol (2009) 1.30
Angiotensin-converting enzyme as a GPIase: a critical reevaluation. Nat Med (2005) 1.28
The involvement of lipid rafts in Alzheimer's disease. Mol Membr Biol (2006) 1.26
Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med (2005) 1.26
Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension (2006) 1.25
The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein. Biochem J (2007) 1.25
The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway. J Biol Chem (2010) 1.21
Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. J Biol Chem (2009) 1.19
The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur J Biochem (2004) 1.18
Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes. Int J Alzheimers Dis (2010) 1.17
Reactive oxygen species-mediated beta-cleavage of the prion protein in the cellular response to oxidative stress. J Biol Chem (2005) 1.12
Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem (2005) 1.10
Visualization of detergent solubilization of membranes: implications for the isolation of rafts. Biophys J (2007) 1.09
alpha-cleavage of the prion protein occurs in a late compartment of the secretory pathway and is independent of lipid rafts. Mol Cell Neurosci (2008) 1.08
Prion protein facilitates uptake of zinc into neuronal cells. Nat Commun (2012) 1.07
Prion protein and Alzheimer disease. Prion (2009) 1.05
The N-terminal region of the prion protein ectodomain contains a lipid raft targeting determinant. J Biol Chem (2003) 1.04
Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry (2003) 1.04
Glypican-1 mediates both prion protein lipid raft association and disease isoform formation. PLoS Pathog (2009) 1.04
The prion protein and neuronal zinc homeostasis. Trends Biochem Sci (2003) 1.04
Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J Alzheimers Dis (2007) 1.04
PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets (2011) 1.02
Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem (2013) 1.01
Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein. J Biol Chem (2011) 1.00
A broad-spectrum fluorescence-based peptide library for the rapid identification of protease substrates. Proteomics (2006) 1.00
The kinetics of phase separation in asymmetric membranes. Biophys J (2005) 0.97
Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem Pharmacol (2007) 0.97
Surface coat remodeling during differentiation of Trypanosoma brucei. J Biol Chem (2003) 0.97
The role of lipid rafts in prion protein biology. Front Biosci (Landmark Ed) (2011) 0.96
ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol (2002) 0.95
Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett (2007) 0.95
Rab GTPase regulation of VEGFR2 trafficking and signaling in endothelial cells. Arterioscler Thromb Vasc Biol (2009) 0.95
N-glycans, not the GPI anchor, mediate the apical targeting of a naturally glycosylated, GPI-anchored protein in polarised epithelial cells. J Cell Sci (2004) 0.94
Prion protein is reduced in aging and in sporadic but not in familial Alzheimer's disease. J Alzheimers Dis (2010) 0.94
The role of zinc in Alzheimer's disease. Int J Alzheimers Dis (2010) 0.94
Efficient expression of secreted proteases via recombinant BacMam virus. Protein Expr Purif (2006) 0.93
Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-beta proteins. Semin Cell Dev Biol (2007) 0.93
Tethering the N-terminus of the prion protein compromises the cellular response to oxidative stress. J Neurochem (2003) 0.92
The Caenorhabditis elegans orthologue of mammalian puromycin-sensitive aminopeptidase has roles in embryogenesis and reproduction. J Biol Chem (2003) 0.90
Effect of hydrophobic mismatch on phase behavior of lipid membranes. Biophys J (2006) 0.90
ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci (2004) 0.89
Alkaline phosphatase is increased in both brain and plasma in Alzheimer's disease. Neurodegener Dis (2011) 0.89
Plasma angiotensin-converting enzyme in Alzheimer's disease. J Alzheimers Dis (2009) 0.87
Secretase-mediated cell surface shedding of the angiotensin-converting enzyme. Protein Pept Lett (2004) 0.87
Emerging and potential therapies for Alzheimer's disease. Expert Opin Ther Targets (2008) 0.87
The bradykinin-degrading aminopeptidase P is increased in women taking the oral contraceptive pill. J Renin Angiotensin Aldosterone Syst (2008) 0.86
Plasma alkaline phosphatase is elevated in Alzheimer's disease and inversely correlates with cognitive function. Int J Mol Epidemiol Genet (2011) 0.85
Structure-activity relationship of hydroxamate-based inhibitors on the secretases that cleave the amyloid precursor protein, angiotensin converting enzyme, CD23, and pro-tumor necrosis factor-alpha. Biochemistry (2002) 0.85
Glycosylation efficiency of Asn-Xaa-Thr sequons is independent of distance from the C-terminus in membrane dipeptidase. Glycobiology (2003) 0.85
Identification and characterisation of the angiotensin converting enzyme-3 (ACE3) gene: a novel mammalian homologue of ACE. BMC Genomics (2007) 0.84
Increased transcription of a potential sigma factor regulatory gene Rv1364c in Mycobacterium bovis BCG while residing in macrophages indicates use of alternative promoters. FEMS Microbiol Lett (2004) 0.84
Association of a GPI-anchored protein with detergent-resistant membranes facilitates its trafficking through the early secretory pathway. Exp Cell Res (2008) 0.83
Membrane raft actin deficiency and altered Ca2+-induced vesiculation in stomatin-deficient overhydrated hereditary stomatocytosis. Biochim Biophys Acta (2007) 0.83
The C-terminal domain, but not the interchain disulphide, is required for the activity and intracellular trafficking of aminopeptidase A. Biochem J (2002) 0.83
Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis. FEBS J (2005) 0.83
Protective effect of prion protein via the N-terminal region in mediating a protective effect on paraquat-induced oxidative injury in neuronal cells. J Neurosci Res (2008) 0.83
BIN1 is decreased in sporadic but not familial Alzheimer's disease or in aging. PLoS One (2013) 0.83
Normalized proliferation of normal and psoriatic keratinocytes by suppression of sAPPalpha-release. J Invest Dermatol (2004) 0.83
Sphingomyelin chain length influences the distribution of GPI-anchored proteins in rafts in supported lipid bilayers. Mol Membr Biol (2007) 0.83
Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stage. PLoS One (2013) 0.83
Muscarine enhances soluble amyloid precursor protein secretion in human neuroblastoma SH-SY5Y by a pathway dependent on protein kinase C(alpha), src-tyrosine kinase and extracellular signal-regulated kinase but not phospholipase C. Brain Res Mol Brain Res (2002) 0.82
Neuronal zinc regulation and the prion protein. Prion (2013) 0.82
A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Hum Mutat (2011) 0.81
Changes of angiotensin-converting enzyme activity in the pancreas of chronic hypoxia and acute pancreatitis. Int J Biochem Cell Biol (2003) 0.81
Distance of sequons to the C-terminus influences the cellular N-glycosylation of the prion protein. Biochem J (2003) 0.81
N-glycans as apical targeting signals in polarized epithelial cells. Biochem Soc Symp (2005) 0.81
Cellular prion protein expression is not regulated by the Alzheimer's amyloid precursor protein intracellular domain. PLoS One (2012) 0.81
The ectodomain shedding of angiotensin-converting enzyme is independent of its localisation in lipid rafts. J Cell Sci (2003) 0.81
Isolation and characterization of glycosylphosphatidylinositol-anchored peptides by hydrophilic interaction chromatography and MALDI tandem mass spectrometry. Anal Chem (2006) 0.80
Regulation of amyloid-β production by the prion protein. Prion (2012) 0.79
Emerging therapeutics for Alzheimer's disease. Expert Rev Neurother (2006) 0.79
Contamination of nuclear fractions with plasma membrane lipid rafts. Proteomics (2007) 0.78
Nitric oxide inhibits the shedding of the glycosylphosphatidylinositol-anchored dipeptidase from porcine renal proximal tubules. Biochem J (2002) 0.78
Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening. Bioorg Med Chem Lett (2009) 0.78
Cellular prion protein protects against reactive-oxygen-species-induced DNA damage. Free Radic Biol Med (2007) 0.77
Development of a high-throughput cell-based assay for 11beta-hydroxysteroid dehydrogenase type 1 using BacMam technology. Mol Biotechnol (2008) 0.77
Glycosyl-phosphatidylinositol (GPI)-anchored renal dipeptidase is released by a phospholipase C in vivo. Kidney Blood Press Res (2002) 0.76
An ACE structure. Nat Struct Biol (2003) 0.76
Presenilin-1 mutations alter K+ currents in the human neuroblastoma cell line, SH-SY5Y. Neuroreport (2002) 0.75
Spontaneous release of glycosylphosphatidylinositol (GPI)-anchored renal dipeptidase from porcine renal proximal tubules. Arch Pharm Res (2002) 0.75
The Role of Tissue Non-specific Alkaline Phosphatase (TNAP) in Neurodegenerative Diseases: Alzheimer's Disease in the Focus. Subcell Biochem (2015) 0.75
Release of renal dipeptidase from glycosylphosphatidylinositol anchor by insulin-triggered phospholipase C/intracellular Ca2+. Arch Pharm Res (2007) 0.75
Discovery of biphenylacetamide-derived inhibitors of BACE1 using de novo structure-based molecular design. J Med Chem (2013) 0.75